Watanabe H, Sherris D, Gilkeson G S
Ralph H. Johnson VA Medical Center and the Department of Medicine, Medical University of South Carolina, Charleston, South Carolina, 29425, USA.
Clin Immunol Immunopathol. 1998 Jul;88(1):91-5. doi: 10.1006/clin.1998.4553.
To determine if soluble CD16 (sCD16) could alter the expression of lupus-like disease, groups of 10 female NZB/NZW mice (age 16-20 weeks) were given sCD16 three times a week for 5 weeks (control; 100 microg; 200 microg/dose) after onset of proteinuria. Results of this study indicate that the administration of sCD16 after onset of disease lowered anti-DNA levels, delayed the development of proteinuria, and significantly prolonged survival while the mice were on treatment. These results indicate that sCD16 alters the expression of autoantibodies and the progression of renal disease in NZB/NZW mice, suggesting that therapies directed at Fc receptors may be useful in the treatment of SLE.
为了确定可溶性CD16（sCD16）是否能改变狼疮样疾病的表现，在蛋白尿出现后，将10只雌性NZB/NZW小鼠（16 - 20周龄）分为几组，每周三次给予sCD16，持续5周（对照组；100微克；200微克/剂量）。本研究结果表明，疾病发作后给予sCD16可降低抗DNA水平，延缓蛋白尿的发展，并在小鼠接受治疗期间显著延长生存期。这些结果表明，sCD16改变了NZB/NZW小鼠自身抗体的表达和肾脏疾病的进展，提示针对Fc受体的疗法可能对系统性红斑狼疮的治疗有用。
